Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 3 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 5fludarabine phosphate 4Azacitidine 4Gemtuzumab 3Decitabine 3Cytarabine 3Busulfan 3venetoclax 2Thiotepa 2Radiotherapy 2Methylprednisolone 2Melphalan 2Filgrastim 2Etoposide 2Antilymphocyte Serum 2vosaroxin 1vedolizumab 1tipifarnib 1midostaurin 1imetelstat 1cedazuridine 1baricitinib 1Whole-Body Irradiation 1Tretinoin 1Tacrolimus 1Stem Cell Transplantation 1Nuclear Receptor Subfamily 4, Group A, Member 2 1Nivolumab 1Methotrexate 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Myelodysplastic Syndromes × cedazuridine × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡